Marinomed Biotech AG Initiates Cash Capital Increase

Marinomed Biotech AG, an Austrian biotech firm, announced a cash capital increase to address short-term capital needs of approximately EUR 2 million. This decision, approved by the Supervisory Board, aims to enhance the company's liquidity until mid-2026. The capital increase will be achieved by issuing up to 459,985 new shares at EUR 14 each, allowing existing shareholders to subscribe on a 4:1 basis. This move comes as Marinomed awaits payments from the Carragelose business transfer to Unither Pharmaceuticals.

The subscription period, beginning March 26, 2026, will end on April 9, 2026. Unsold shares will be offered via a private placement. An institutional investor has committed to acquire shares worth EUR 1 million. The share issuance is exempt from certain regulatory requirements under the EU Prospectus Regulation.